Lab Anim Res.  2014 Sep;30(3):131-135. 10.5625/lar.2014.30.3.131.

Anti-Helicobacter pylori activities of FEMY-R7 composed of fucoidan and evening primrose extract in mice and humans

• Kim TS
• Choi EK
• Kim J
• Shin K
• Lee SP
• Choi Y
• Jeon JH
• Kim YB

• KMID: 2312124
• DOI: http://doi.org/10.5625/lar.2014.30.3.131

Abstract

Helicobacter pylori-eliminating effects of FEMY-R7, composed of fucoidan and evening primrose extract, were investigated in mice and humans. Male C57BL/6 mice were infected with the bacteria by intragastric inoculation (1x10(9) CFU/mouse) 3 times at 2-day intervals, and simultaneously, orally treated twice a day with 10 or 100 mg/kg FEMY-R7 for 2 weeks. In Campylobcter-like organism-detection test, FEMY-R7 markedly reduced the urease-positive reactivity. In a clinical sudy, human subjects, confirmed to be infected with Helicobacter pylori, were orally administered twice a day with a capsule containing 150 mg FEMY-R7 for 8 weeks. FEMY-R7 significantly decreased both the Delta over baseline-value in urea breath test and the serum pepsinogens I and II levels. The results indicate that FEMY-R7 not only eliminates H. pylori from gastric mucosa of animals and humans, but also improves gastric function.

Keyword

Helicobacter pylori; FEMY-R7; fucoidan; evening primrose extract; Campylobcter-like organism-detection test; urea breath test; pepsinogen

MeSH Terms

Animals
Bacteria
Breath Tests
Gastric Mucosa
Helicobacter
Helicobacter pylori
Humans
Male
Mice*
Oenothera biennis*
Pepsinogen A
Pepsinogens
Urea
Pepsinogen A
Pepsinogens
Urea

Figure

• 

  Figure 1 Effect of FEMY-R7 (300 mg/day) on the Delta over baseline-value (DOB, ‰) in urea breath test (UBT) on the expiratory breath of patients infected with H. pylori. White: placebo, black: FEMY-R7. *Significantly different from before treatment (0 time). #Significantly different from placebo (8 week).

Reference

1. Wallace JL, Granger DN. The cellular and molecular basis of gastric mucosal defense. FASEB J. 1996; 10(7):731–740. PMID: 8635690.

2. Neal MJ. Medical Pharmacology at a Glance. 3rd ed. London: Blackwell Publishing Inc;2003. p. 30–31.

3. Isobe H, Okajima K, Harada N, Liu W, Okabe H. Activated protein C reduces stress-induced gastric mucosal injury in rats by inhibiting the endothelial cell injury. J Thromb Haemost. 2004; 2(2):313–320. PMID: 14995995.

4. Byun SK, Lee YE, Shin SH, Jang JY, Choi BI, Park DS, Jeon JH, Nahm SS, Hwang SY, Kim YB. The role of corticosteroids in stress-induced gastric ulceration in rats. Lab Anim Res. 2007; 23(2):127–131.

5. Slomiany BL, Piotrowski J, Slomiany A. Induction of tumor necrosis factor-alpha and apoptosis in gastric mucosal injury by indomethacin: effect of omeprazole and ebrotidine. Scand J Gastroenterol. 1997; 32(7):638–642. PMID: 9246701.

6. Filaretova L, Tanaka A, Miyazawa T, Kato S, Takeuchi K. Mechanisms by which endogenous glucocorticoid protects against indomethacin-induced gastric injury in rats. Am J Physiol Gastrointest Liver Physiol. 2002; 283(5):G1082–G1089. PMID: 12381521.

7. Cao H, Wang MW, Jia JH, Wang QG, Cheng MS. Comparison of the effects of pantoprazole enantimers on gastric mucosal lesions and gastric epithelial cells in rats. J Health Sci. 2004; 50(1):1–8.

8. Rao ChV, Ojha SK, Radhakrishnan K, Govindarajan R, Rastogi S, Mehrotra S, Pushpangadan P. Antiulcer activity of Utleria salicifolia rhizome extract. J Ethnopharmacol. 2004; 91(2-3):243–249. PMID: 15120446.

9. Kim YR, Lee MR, Kim YH, Jang BJ, Park SC, Han SH, Kim BH, Ryoo ZY, Kim KS. Effect of Opuntiahumifusa extract on indomethacin-induced gastric ulcer in Sprague Dawley rat. Lab Anim Res. 2005; 21(4):375–578.

10. Raffin RP, Colomé LM, Schapoval EE, Jornada DS, Pohlmann AR, Guterres SS. Gastro-resistant microparticles containing sodium pantoprazole: stability and in vivo anti-ulcer activity. Open Drug Deliv J. 2007; 1:28–35.

11. Dias PC, Foglio MA, Possenti A, de Carvalho JE. Antiulcerogenic activity of crude hydroalcoholic extract of Rosmarinus officinalis L. J Ethnopharmacol. 2000; 69(1):57–62. PMID: 10661884.

12. Cantarella G, Martinez G, Cutuli VM, Loreto C, D'Alcamo M, Prato A, Amico-Roxas M, Bernardini R, Clementi G. Adrenomedullin modulates COX-2 and HGF expression in reserpine-injuried gastric mucosa in the rat. Eur J Pharmacol. 2005; 518(2-3):221–226. PMID: 16081063.

13. Cantarella G, Martinez G, Di Benedetto G, Loreto C, Musumeci G, Prato A, Lempereur L, Matera M, Amico-Roxas M, Bernardini R, Clementi G. Protective effects of amylin on reserpine-induced gastric damage in the rat. Pharmacol Res. 2007; 56(1):27–34. PMID: 17412609.

14. Işbil Büyükcoşkun N, Güleç G, Ozlük K. Protective effect of centrally-injected glucagon-like peptide-1 on reserpine-induced gastric mucosal lesions in rat: possible mechanisms. Turk J Gastroenterol. 2006; 17(1):1–6. PMID: 16830270.

15. Pope AJ, Toseland CD, Rushant B, Richardson S, McVey M, Hills J. Effect of potent urease inhibitor, fluorofamide, on Helicobacter sp. in vivo and in vitro. Dig Dis Sci. 1998; 43(1):109–119. PMID: 9508511.

16. Hahm KB, Kim DH, Lee KM, Lee JS, Surh YJ, Kim YB, Yoo BM, Kim JH, Joo HJ, Cho YK, Nam KT, Cho SW. Effect of long-term administration of rebamipide on Helicobacter pylori infection in mice. Aliment Pharmacol Ther. 2003; 18(Suppl 1):24–38. PMID: 12925138.

17. Aristoteli LP, O'Rourke JL, Danon S, Larsson H, Mellgard B, Mitchell H, Lee A. Urea, fluorofamide, and omeprazole treatments alter helicobacter colonization in the mouse gastric mucosa. Helicobacter. 2006; 11(5):460–468. PMID: 16961809.

18. Coghlan JG, Gilligan D, Humphries H, McKenna D, Dooley C, Sweeney E, Keane C, O'Morain C. Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study. Lancet. 1987; 2(8568):1109–1111. PMID: 2890019.

19. Graham DY, Evans DG, Evans DJ Jr. Campylobacter pylori. The organism and its clinical relevance. J Clin Gastroenterol. 1989; 11(Suppl 1):S43–S48. PMID: 2809138.

20. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991; 338(8776):1175–1176. PMID: 1682595.

21. Cover TL, Blaser MJ. Helicobacter pylori and gastroduodenal disease. Annu Rev Med. 1992; 43:135–145. PMID: 1580578.

22. Lee A, Fox J, Hazell S. Pathogenicity of Helicobacter pylori: a perspective. Infect Immun. 1993; 61(5):1601–1610. PMID: 8478048.

23. Marshall BJ. Helicobacter pylori in peptic ulcer: have Koch's postulates been fulfilled? Ann Med. 1995; 27(5):565–568. PMID: 8541033.

24. Zhang Z, Liu ZQ, Zheng PY, Tang FA, Yang PC. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastroenterol. 2010; 16(10):1279–1284. PMID: 20222174.

25. Feldman SC, Reynaldi S, Stortz CA, Cerezo AS, Damont EB. Antiviral properties of fucoidan fractions from Leathesia difformis. Phytomedicine. 1999; 6(5):335–340. PMID: 11962540.

26. Wang J, Zhang Q, Zhang Z, Song H, Li P. Potential antioxidant and anticoagulant capacity of low molecular weight fucoidan fractions extracted from Laminaria japonica. Int J Biol Macromol. 2010; 46(1):6–12. PMID: 19883681.

27. Bojakowski K, Abramczyk P, Bojakowska M, Zwoliñska A, Przybylski J, Gaciong Z. Fucoidan improves the renal blood flow in the early stage of renal ischemia/reperfusion injury in the rat. J Physiol Pharmacol. 2001; 52(1):137–143. PMID: 11321507.

28. Li N, Zhang Q, Song J. Toxicological evaluation of fucoidan extracted from Laminaria japonica in Wistar rats. Food Chem Toxicol. 2005; 43(3):421–426. PMID: 15680677.

29. Shibata H, Iimuro M, Uchiya N, Kawamori T, Nagaoka M, Ueyama S, Hashimoto S, Yokokura T, Sugimura T, Wakabayashi K. Preventive effects of Cladosiphon fucoidan against Helicobacter pylori infection in Mongolian gerbils. Helicobacter. 2003; 8(1):59–65. PMID: 12603617.

30. Shibata H, KimuraTakagi I, Nagaoka M, Hashimoto S, Sawada H, Ueyama S, Yokokura T. Inhibitory effect of Cladosiphon fucoidan on the adhesion of Helicobacter pylori to human gastric cells. J Nutr Sci Vitaminol (Tokyo). 1999; 45(3):325–336. PMID: 10524351.

31. Funatogawa K, Hayashi S, Shimomura H, Yoshida T, Hatano T, Ito H, Hirai Y. Antibacterial activity of hydrolyzable tannins derived from medicinal plants against Helicobacter pylori. Microbiol Immunol. 2004; 48(4):251–261. PMID: 15107535.

32. Kamiya S, Osaki T, Yamaguci H, Shimada T, Okada T, Takahashi Y. Effect of evening primrose extract on growth, adhesion and colonization of Helicobacter pylori. Bact Adherence Bofilm. 2003; 17:16–19.

33. Cai J, Kim TS, Jang JY, Kim J, Shin K, Lee SP, Choi EK, Kim SH, Park M, Kim JB, Kim YB. In vitro and in vivo anti-Helicobacter pylori activities of FEMY-R7 composed of fucoidan and evening primrose extract. Lab Anim Res. 2014; 30(1):28–34. PMID: 24707302.

34. Yang YH, Park D, Yang G, Lee SH, Bae DK, Kyung J, Kim D, Choi EK, Son JC, Hwang SY, Kim YB. Anti-Helicobacter pylori effects of IgY from egg york of immunized hens. Lab Anim Res. 2012; 28(1):55–60. PMID: 22474475.

35. Mattar R, Villares CA, Marostegam PF, Chaves CE, Pinto VB, Carrilho FJ. Low dose capsule based 13c-urea breath test compared with the conventional 13c-urea breath test and invasive tests. Arq Gastroenterol. 2014; 51(2):133–138. PMID: 25003266.

36. Oh DH, Lee DH, Kang KK, Park YS, Shin CM, Kim N, Yoon H, Hwang JH, Jeoung SH, Kim JW, Jang ES, Jung HC. The efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. J Gastroenterol Hepatol. 2014; 29(6):1171–1176. PMID: 24955448.

37. Chobot A, Bak-Drabik K, Skała-Zamorowska E, Krzywicka A, Kwiecieñ J, Polañska J. Helicobacter pylori infection in type 1 diabetes children and adolescents using 13C urea breath test. Pol J Microbiol. 2014; 63(1):63–67. PMID: 25033664.

38. Choi HS, Lee SY, Kim JH, Sung IK, Park HS, Shim CS, Jin CJ. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm. J Dig Dis. 2014; 15(6):293–298. PMID: 24602176.

39. Massarrat S, Haj-Sheykholeslami A, Mohamadkhani A, Zendehdel N, Aliasgari A, Rakhshani N, Stolte M, Shahidi SM. Pepsinogen II can be a potential surrogate marker of morphological changes in corpus before and after H. pylori eradication. Biomed Res Int. 2014; 2014:481607. PMID: 25028655.

40. Leja M, Lapina S, Polaka I, Rudzite D, Vilkoite I, Daugule I, Belkovets A, Pimanov S, Makarenko J, Tolmanis I, Lejnieks A, Boka V, Rumba-Rozenfelde I, Vikmanis U. Pepsinogen testing for evaluation of the success of Helicobacter pylori eradication at 4 weeks after completion of therapy. Medicina (Kaunas). 2014; 50(1):8–13. PMID: 25060199.

41. Mukoubayashi C, Yanaoka K, Ohata H, Arii K, Tamai H, Oka M, Ichinose M. Serum pepsinogen and gastric cancer screening. Intern Med. 2007; 46(6):261–266. PMID: 17379991.

42. Sipponen P, Härkönen M, Alanko A, Suovaniemi O. Diagnosis of atrophic gastritis from a serum sample. Clin Lab. 2002; 48(9-10):505–515. PMID: 12389711.

43. Daw MA, Deegan P, Leen E, O'Moráin C. Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis. Aliment Pharmacol Ther. 1991; 5(4):435–439. PMID: 1777552.

44. Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, Tamura T, Imada A. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother. 1991; 35(3):490–496. PMID: 2039199.

45. Hunt RH. Eradication of Helicobacter pylori infection. Am J Med. 1996; 100(5A):42S–51S. PMID: 8644782.

46. Samloff IM. Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology. 1971; 61(2):185–188. PMID: 4935210.

47. Samloff IM, Liebman WM. Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology. 1973; 65(1):36–42. PMID: 4124404.

48. Korstanje A, den Hartog G, Biemond I, Lamers CB. The serological gastric biopsy: a non-endoscopical diagnostic approach in management of the dyspeptic patient: significance for primary care based on a survey of the literature. Scand J Gastroenterol Suppl. 2002; 236:22–26. PMID: 12408500.